By Bhanvi Satija Dec 15 (Reuters) - French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

Dec 16 (Reuters) - South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...

Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Korean biopharmaceutical company Adel announced Monday that it has secured a license-out agreement worth up to $1.04 billion ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...